The pharmacology of TD-8954, a potent and selective 5-HT4 receptor agonist with gastrointestinal prokinetic properties

David T. Beattie1*, Scott R. Armstrong1, Ross G. Vickery2, Pamela R. Tsuruda3, Christina B. Campbell1, Carrie Richardson4, Julia L. McCullough4, Oranee Daniels2, Kathryn Kersey2, Yu-Ping Li5 and Karl H. S. Kim2

1 Department of Pharmacology, Theravance, Inc., South San Francisco, CA, USA
2 Department of Clinical Pharmacology and Experimental Medicine, Theravance, Inc., South San Francisco, CA, USA
3 Department of Molecular and Cellular Biology, Theravance, Inc., South San Francisco, CA, USA
4 Formerly of Theravance, Inc., South San Francisco, CA, USA
5 Department of Biometrics, Theravance Inc., South San Francisco, CA, USA

E-mail: dbeattie@theravance.com

This study evaluated the in vitro and in vivo pharmacological properties of TD-8954, a potent and selective 5-HT4 receptor agonist. TD-8954 had high affinity (pKᵢ = 9.4) for human recombinant 5-HT4(c) (h5-HT4(c)) receptors, and selectivity (>2,000-fold) over all other 5-hydroxytryptamine (5-HT) receptors and non-5-HT receptors, ion channels, enzymes and transporters tested (n = 78). TD-8954 produced an elevation of cAMP in HEK-293 cells expressing the h5-HT4(c) receptor (pEC50 = 9.3), and contracted the guinea pig colonic longitudinal muscle/myenteric plexus preparation (pEC50 = 8.6). TD-8954 had moderate intrinsic activity in the in vitro assays. In conscious guinea pigs, subcutaneous administration of TD-8954 (0.03–3 mg/kg) increased the colonic transit of carmine red dye, reducing the time taken for its excretion. Following intraduodenal dosing to anesthetized rats, TD-8954 (0.03–10 mg/kg) evoked a dose-dependent relaxation of the esophagus. Following oral administration to conscious dogs, TD-8954 (10 and 30 μg/kg) produced an increase in contractility of the antrum, duodenum, and jejunum. In a single ascending oral dose study in healthy human subjects, TD-8954 (0.1–20 mg) increased bowel movement frequency and reduced the time to first stool. It is concluded that TD-8954 is a potent and selective 5-HT4 receptor agonist in vitro, with robust in vivo stimulatory activity in the gastrointestinal (GI) tract of guinea pigs, rats, dogs, and humans. TD-8954 may have clinical utility in patients with disorders of reduced GI motility.

Keywords: constipation, serotonin, 5-HT4, prokinetic, TD-8954

INTRODUCTION

5-Hydroxytryptamine (5-HT) plays a critical role in coordinating gastrointestinal (GI) transit (Hansen and Skadhauge, 1997; Grider et al., 1998; Jin et al., 1999; Baker, 2005). In response to intestinal stretching and mucosal stimulation, 5-HT is released from enterochromaffin cells of the mucosal epithelium, and promotes peristalsis via activation of intrinsic primary afferent neurons located in the submucous plexus (Kirchgesner et al., 1992; Foxx-Orenstein et al., 1995; Gershon and Tack, 2007). Of the 5-HT receptors believed to influence GI motility (e.g., 5-HT1A, 5-HT2A, 5-HT2B, 5-HT3, and 5-HT4; Beattie and Smith, 2008), the 5-HT4 receptor subtype is considered particularly important, both physiologically and pathophysiologically (Kadowaki et al., 1996; Kim and Camilleri, 2000; Baker, 2005). The peristaltic reflex, for example, is dependent on activation of 5-HT4 receptors on intrinsic primary afferent neurons, interneurons, and motor neurons within the gut wall, which results in the coordinated release of acetylcholine, substance P, and calcitonin gene-related peptide. The release of these agents is associated with synchronized contraction and relaxation of GI smooth muscle, and propulsion of luminal contents (Jin et al., 1999; Gershon and Tack, 2007). Additionally, activation of 5-HT4 receptors in the smooth muscle of the human distal colon, and on enteric neurons or enterocytes promotes a direct relaxant effect and fluid secretion, respectively, further supporting GI transit (Hillier et al., 1994; Hansen and Skadhauge, 1997).

Agents interacting with 5-HT3 and 5-HT4 receptors have provided meaningful benefit to patients with GI functional disorders (Sanger, 2008). The GI prokinetic activity of 5-HT4 receptor agonists, such as tegaserod (Zelnorm®), cisapride (Propulsid®), velusetrag (TD-5108), prucalopride (Resolor®), and mosapride has been demonstrated in a variety of species (Jin et al., 1999; Briejer et al., 2001b; Inui et al., 2002; Ji et al., 2003; Manini et al., 2009), and clinical efficacy has been established in patients with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation, functional dyspepsia, or gastroparesis (Deruyttere et al., 1987; Muller-Lissner, 1987; Abell et al., 1991; Camilleri, 2001; Johanson, 2004; Patel et al., 2004; Camilleri et al., 2008; Goldberg et al., 2010). Cisapride and tegaserod were used widely to treat upper and lower GI disorders of reduced motility, respectively, although their clinical efficacy in many patients was modest (Kellow et al., 1995; Evans et al., 2004), possibly reflecting their interactions with receptors other than the 5-HT4 subtype (Briejer et al., 1995; Beattie et al., 2004; Beattie and Smith, 2008; De Maeyer et al., 2008). The clinical use of cisapride and tegaserod is now restricted on the basis of cardiovascular safety concerns...
All animal experiments were conducted in accordance with the United States Code of Federal Regulations and the principles of the Declaration of Helsinki. In this study, the in vitro and in vivo pharmacodynamic properties of a structurally novel 5-HT₄ receptor agonist, TD-8954 (4-(4-{(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino}[methyl]-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester; Figure 1), have been investigated. The preclinical activity of several standard 5-HT₄ agonists was evaluated in parallel for comparison to that of TD-8954.

MATERIALS AND METHODS

All animal experiments were conducted in accordance with the principles of good laboratory animal care provided by the Institutional Animal Care and Use Committees of Theravance, Inc. (rodent studies) or Drug Research Laboratories (dog study). The study protocol and consent form for the human single ascending dose study were reviewed by the clinical site's Institutional Review Board, and each volunteer provided written informed consent prior to initiation of study procedures. The study was conducted at a single site in accordance with the United States Code of Federal Regulations and the principles of the Declaration of Helsinki.

HUMAN RECOMBINANT 5-HT₄ RECEPTORS

Radioligand binding

Radioligand binding studies were conducted as described previously (Smith et al., 2008). Inhibition of [³H]-GR113808 binding was measured using membranes prepared from HEK293 cells stably expressing the human 5-HT₄⁶(c) (h5-HT₄⁶(c)) receptor splice variant (HEK293-h5-HT₄⁶(c)) (Kaumann and Levy, 2006)

5-HT₄⁶(c) receptor mRNA was been detected in human GI tissue by RT-PCR (Blondel et al., 1998; Bender et al., 2000; Medhurst et al., 2001; Ito et al., 2003), and the rank order of affinities or potencies for several agonist and antagonists is maintained across 5-HT₄ receptor splice variants in published reports (Blondel et al., 1998; Smith et al., 2008), supporting the use of the 5-HT₄⁶(c) variant for the current studies. Unlabeled compound (10 pM to 100 μM) was incubated for 1 h at room temperature with [³H]-GR113808 (0.15 nM) and h5-HT₄⁶(c) membranes (2 μg protein) in a total assay volume of 400 μL. Binding reactions were terminated by rapid filtration over GF/B filter plates and bound radioactivity quantitated by liquid scintillation spectroscopy in Microscint-20 using a TopCount Scintillation Counter (Packard BioScience, Meriden, CT, USA).

Binding data were analyzed by non-linear regression analysis using GraphPad PrismTM software (GraphPad Software, Inc., San Diego, CA, USA) and a three-parameter model for one-site competition. The pKᵢ (negative decadic logarithm of Kᵢ) values for test compounds were calculated from the best-fit IC₅₀ values, and the K₄ value of the radioligand, using the Cheng–Prusoff equation [Cheng and Prusoff, 1973; K₄ = IC₅₀/(1 + [L]/Kᵢ)] where [L] = radioligand concentration], and are reported as the mean ± SEM. Standard compounds were evaluated in parallel with TD-8954; the pKᵢ values were consistent with those reported previously (Vickery et al., 2007; Smith et al., 2008).

Whole cell cAMP accumulation

Whole cell cAMP accumulation assays were performed as described previously (Smith et al., 2008) using a homogeneous radioimmunoassay (Flashplate Adenylyl Cyclase Activation Assay System; Perkin Elmer Life Sciences, Boston, MA, USA). HEK293-h5-HT₄⁶(c) cells were lifted in Versene and collected by centrifugation (1,200 × g, 5 min) in phosphate-buffered saline (PBS). The cell pellet was resuspended gently in warm “stimulation buffer” (provided in the assay kit) and diluted to 5 × 10⁵ cells/mL. Cells (25,000 per well) were incubated with test compound (10 pM to 100 μM) for 15 min at 37°C in a 96-well Flashplate, in a total volume of 0.1 mL. In antagonist inhibition studies, cells were preincubated in the absence or presence of GR113808 (0.6, 1.7, or 5 nM) for 20 min at 37°C prior to the addition of the test agonist. After the incubation period, [¹²⁵I]-cAMP was added in 100 μL of ice-cold “detection buffer” to each well, according to the manufacturer’s instructions. Bound radioactivity was quantified by scintillation counting and the amount of CAMP produced was extrapolated from a CAMP standard curve.

Data were analyzed by non-linear regression analysis with GraphPad Prism™ using the three-parameter sigmoidal concentration–effect model (slope constrained to unity). The potency of test agents was reported as a mean (±SEM) pEC₅₀ value (negative decadic logarithm of the effective concentration producing 50% of the maximum response), and the intrinsic activity (IA) as a mean (±SEM) percentage of the maximum 5-HT-evoked response. The pEC₅₀ and IA values for standard compounds (tested in parallel with TD-8954) were consistent with those reported previously (Vickery et al., 2007; Smith et al., 2008). Schild regression analysis was used to determine pKᵢ₆ values for GR113808 in the antagonist inhibition studies for 5-HT and TD-8954 (Kenakin, 1997). Concentration ratios (CR) were calculated
as the ratio of the EC$_{50}$ values in the presence and absence of antagonist. The log[CR-1] was plotted against the log[GR113808], resulting in a linear relationship with the slope not significantly different from unity. The slope was therefore constrained to unity, and the X-intercept was extrapolated to provide a measure of the pK$_{50}$ value for GR113808.

**5-HT$_4$ receptor selectivity**

Off-target selectivity screening was conducted at Theravance, Inc. or at a contract research organization (CEREP, Paris, France). Conventional radioligand binding studies were conducted using, in the majority of assays, membranes prepared from cell lines transfected with the respective human recombinant receptor, ion channel, or transporter. The percent inhibition of specific binding by TD-8954, at a single concentration (1 μM, in duplicate), was determined. Conventional whole cell voltage-clamp techniques were used to examine the interaction of TD-8954 (3 μM) and neuronal (rat Na$_v$1.2) and cardiac (human Na$_v$1.5) voltage-gated sodium channels and hERG potassium channels (see Smith et al., 2006, 2008).

**Functional 5-HT$_4$ receptor activity in the guinea pig colonic longitudinal muscle/myenteric plexus**

Adult, male Dunkin Hartley guinea pigs (200–350 g, Harlan, Chicago, IL, USA) were euthanized by CO$_2$ asphyxiation. The mid-scapular area and abdomen were shaved and cleansed with betadine and 70% isopropanol. A small incision was made in the lower abdomen to expose the proximal colon. After isolation, a small incision was made in the proximal colon (approximately 2 cm from the cecum) and a cannula consisting of micro-renathene (MRE-040) tubing with a 2-cm silicone rubber tip (RenaSil™; 0.047" OD × 0.025" ID) was introduced and advanced approximately 2 cm toward the aboral end. A purse-string suture (Ethicon, 6-0 silk) was used to anchor the cannula in the colon and Baytril antibiotic (2.27%) was then applied topically to the colonic surgical site. The muscle layer was closed with a 4-0 Vicryl suture. The cannula was then secured to the nearby musculature with a 6-0 silk suture, tunneled under the skin and exteriorized at the mid-scapular region. The cannula was flushed and locked with sterile saline (Baxter), sealed with a sterile stainless steel pin, and secured to the back of the neck with a wound clip. The incisions in the peritoneum and abdomen were cleaned of blood and closed with a 3-0 Ethilon suture (Ethicon). Subcutaneous (s.c.) warmed lactated-Ringer’s solution (3 mL) was administered immediately after surgery in addition to an intramuscular injection of the opioid analgesic, Buprenex® (buprenorphine, 0.05 mg/kg).

At least 5 days after surgery, guinea pigs were assigned randomly to a study group. Animals were dosed with test agent or vehicle (2 mL/kg s.c.), and 5 min later, each guinea pig was gently restrained and a non-absorbable marker (0.2 mL) was infused into the proximal colon via the implanted cannula. The marker consisted of 6 g of carmine red dye per 15 mL of carboxymethyl cellulose (0.5%). The study personnel were blinded to the treatment that each animal received. Animal cages were visually inspected for the presence of excreted red fecal pellets at 30-min intervals until each guinea pig had excreted pellets containing the red marker, or until 10 h had lapsed from the time of the marker injection. In the case that an animal failed to produce red fecal pellets within 10 h, the animal was left overnight in a clean cage and inspected the following morning. If excretion of dye occurred overnight, a value of 10 h was assigned. The whole colonic transit was defined as the time that lapsed between marker injection and the appearance of dye in the feces. Data for each treatment group were expressed as a mean percent increase (±SEM) in colonic transit time relative to vehicle-treated animals. Differences between treatment groups were determined using one-way analysis of variance.
tionship with variable slope, and an ED50 value (i.e., the dose that results in 50% of the maximum response) was calculated using a single oral dose of TD-8954 (0.1, 0.5, 1, 2, 5, 10, or 20 mg) and two subjects received placebo. The lowest dose of TD-8954 was formulated as an aqueous solution, while the other doses were formulated with isoflurane (2–3%) in an induction chamber and anesthesia was maintained with isoflurane (2–3%) via a nose cone for the duration of each experiment. Animals were placed, in a supine position, on a heated pad to maintain body temperature at 37–38°C [monitored rectally with a sensor (Physitemp BAT-12)]. A midline incision was made in the skin and muscle layers of the abdomen, and the stomach and esophagus were exposed. A small incision was made in the upper duodenum approximately 1 cm from the pyloric sphincter, to permit intraduodenal (i.d.) administration of test agents. A micro-renathane catheter (MRE-40 with a 1 cm RenaSil rubber tip) was inserted approximately 1.5 cm into the duodenum via the incision and closed with 6-0 silk purse-string suture. Two piezoelectric crystals (1 mm diameter; Sonometrics Corp.) were gently glued, in a longitudinal orientation, to the distal esophagus (1 cm from the lower esophageal sphincter) using Vetbond tissue adhesive. The inter-crystal distance was approximately 2 mm. The wires connecting the crystals to the measurement device (Sonometrics Corp. TRX series 8) were exteriorized through the abdominal incision site, which was then closed with 4-0 Ethilon suture.

Following surgery, baseline esophageal tone was allowed to stabilize over approximately 30 min, prior to drug administration. The settings for the Sonometrics system were fixed within the Sonoview software (Sonometrics Corp., version 3.2.1) as follows: sampling rate = 99.4 Hz, transmit pulse = 375 ns, inhibit delay = 1.2–1.5 mm, velocity of sound through biological tissue = 1.59 mm/μs. Drug vehicle, followed by increasing doses of test compounds (0.5 mL/kg) were administered cumulatively to the duodenal cannula. Each dose was administered only when the esophageal response to the preceding dose had reached a maximum (typically 15–20 min). Changes in inter-crystal distance (in mm) from resting levels were averaged for each treatment group. The data were fitted to a sigmoidal dose–response relation (in mm) from resting levels were averaged for each treatment group. An ANOVA with a Dunnett’s post hoc test (p < 0.05 considered to be statistically significant).

RAT ESOPHAGEAL RELAXATION

The technique of digital sonomicrometry was used (Adelson and Million, 2004; Armstrong et al., 2006). Adult, male Sprague-Dawley rats (250–350 g, Harlan, Chicago, IL, USA) were acclimated to the colony room (temperature controlled at 21 ± 1°C and 12:12 h light–dark cycle commencing at 7 a.m.) for at least 5 days prior to intervention. Standard rat diet (Harlan Teklad) and drinking water were available ad libitum. Rats were anesthetized with isoflurane (2–3%) in an induction chamber and anesthesia was then maintained with isoflurane (2–3%) via a nose cone for the duration of each experiment. Animals were placed, in a supine position, on a heated pad to maintain body temperature at 37–38°C [monitored rectally with a sensor (Physitemp BAT-12)]. A midline incision was made in the skin and muscle layers of the abdomen, and the stomach and esophagus were exposed. A small incision was made in the upper duodenum approximately 1 cm from the pyloric sphincter, to permit intraduodenal (i.d.) administration of test agents. A micro-renathane catheter (MRE-40 with a 1 cm RenaSil rubber tip) was inserted approximately 1.5 cm into the duodenum via the incision and closed with 6-0 silk purse-string suture. Two piezoelectric crystals (1 mm diameter; Sonometrics Corp.) were gently glued, in a longitudinal orientation, to the distal esophagus (1 cm from the lower esophageal sphincter) using Vetbond tissue adhesive. The inter-crystal distance was approximately 2 mm. The wires connecting the crystals to the measurement device (Sonometrics Corp. TRX series 8) were exteriorized through the abdominal incision site, which was then closed with 4-0 Ethilon suture.

Following surgery, baseline esophageal tone was allowed to stabilize over approximately 30 min, prior to drug administration. The settings for the Sonometrics system were fixed within the Sonoview software (Sonometrics Corp., version 3.2.1) as follows: sampling rate = 99.4 Hz, transmit pulse = 375 ns, inhibit delay = 1.2–1.5 mm, velocity of sound through biological tissue = 1.59 mm/μs. Drug vehicle, followed by increasing doses of test compounds (0.5 mL/kg) were administered cumulatively via the duodenal cannula. Each dose was administered only when the esophageal response to the preceding dose had reached a maximum (typically 15–20 min). Changes in inter-crystal distance (in mm) from resting levels were averaged for each treatment group. The data were fitted to a sigmoidal dose–response relation (in mm) from resting levels were averaged for each treatment group. An ANOVA with a Dunnett’s post hoc test (p < 0.05 considered to be statistically significant).

HUMAN SINGLE ASCENDING DOSE STUDY

A Phase 1, double-blind, randomized, placebo-controlled, single ascending dose study was performed, consisting of seven sequential cohorts. In each cohort, eight healthy male and female subjects (18–50 years old) were randomized such that six subjects received a single oral dose of TD-8954 (0.1, 0.5, 1, 2, 5, 10, or 20 mg) and two subjects received placebo. The lowest dose of TD-8954 was formulated as an aqueous solution, while the other doses were administered as a powder in capsule. All subjects were confined to the clinical research unit from day 1 (admission) until after the 48-h post-dose safety assessments, and then returned on day 7 for a follow-up visit. A bowel diary was used to record the date and time of each bowel movement after dosing. The bowel diary was reviewed daily and before discharge. Blood samples were collected to assess the pharmacokinetics of TD-8954, and safety and tolerability were closely monitored.

MATERIALS

Standard biochemical and tissue culture reagents were purchased from Sigma-Aldrich (St Louis, MO, USA) and Invitrogen (Carlsbad, CA, USA) respectively. [3H]GR113808 was purchased from Amersham Biosciences (Newark, NJ, USA). The Flashplate Adenylyl Cyclase Activation Assay System was purchased from PerkinElmer (Boston, MA, USA). TD-8954, prucalopride, mosapride, and piboserod were synthesized at Theravance, Inc. GR113808, tegaserod and cisapride were purchased from Tocris Cookson (Ellisville, MO, USA), Apin Chemicals (Abingdon, Oxon, UK) and...
Sequoia Research Products (Pangbourne, UK), respectively. Carbachol, 5-HT, and ketanserin were purchased from Sigma-Aldrich.

For in vitro radioligand binding and cAMP accumulation studies, stock agonist solutions (10 mM) were prepared in DMSO, diluted to 400 μM with 50 mM HEPES (pH 7.4) at 25°C, containing 0.1% BSA, and serial dilutions prepared in the same buffer. For isolated tissue studies, 10 mM solutions, prepared in DMSO, were diluted serially in sterile water. For in vivo studies, TD-8954 and prucalopride were dissolved in 5% dextrose in distilled water (D5W) or 0.9% saline, while tegaserod and mosapride were prepared in 10% sulfobutyl ether-beta cyclodextrin (10% SBE/CD), and cisapride was dissolved in 10% SBE/CD containing citrate (20 mM). Doses were expressed with respect to the free base weights of each compound.

RESULTS

5-HT4 RECEPTOR BINDING AND cAMP ACCUMULATION

TD-8954, tegaserod, prucalopride, cisapride, and mosapride produced a concentration-dependent inhibition of [3H]-GR113808 binding to HEK293-h5-HT4(c) cell membranes. Comparison of the mean pKi values for the compounds (Table 1) indicated a rank order of affinity of TD-8954 (pKi = 9.4) > tegaserod (pKi = 8.6) > prucalopride (pKi = 7.6) > cisapride (pKi = 7.1) > mosapride (pKi = 6.8). In cAMP accumulation assays, using HEK-293 cells stably transfected with the h5-HT4(c) receptor, TD-8954, tegaserod, cisapride, prucalopride, and mosapride produced a concentration-dependent increase in cAMP. The rank order of potency was TD-8954 (pEC50 = 9.3) > tegaserod (pEC50 = 8.7) > prucalopride (pEC50 = 7.9) > cisapride (pEC50 = 7.4) > mosapride (pEC50 = 6.3). The mean IAs of TD-8954, tegaserod, cisapride, prucalopride, and mosapride, relative to 5-HT (100%) were 83, 120, 101, 109, and 22%, respectively; Table 1). In antagonist inhibition studies, increasing concentrations of GR113808 produced rightward shifts in the 5-HT and TD-8954 concentration–response curves, resulting in pKb values (with 95% confidence intervals) of 10.3 (95% CI: 10.2–10.4) and 10.3 (95% CI: 10.2–10.5), respectively.

5-HT4 RECEPTOR SELECTIVITY

TD-8954 was >2,000-fold selective for h5-HT4(c) receptors over other 5-HT receptors (Table 2), and all non-5-HT receptors, transporters, ion channels, and enzymes tested (Table 3). TD-8954 (3 μM) had no effect on hERG potassium currents (n = 6 cells) while cisapride (20 nM) was associated with a mean inhibition of 65% in the same cells. Exposure to TD-8954 (3 μM) for 3 min had no effect on the magnitude of the inward rat Na+,L.2a or human Na+,1.5 sodium currents (n = 3 cells for each).

GUINEA PIG COLONIC LONGITUDINAL MUSCLE/MYENTERIC PLEXUS

TD-8954, tegaserod, cisapride, prucalopride, and mosapride produced concentration-dependent contraction of the guinea pig colonic LMMP (Figure 2). Comparison of the mean pEC50 (±SEM) values for the compounds indicated a rank order of potency of TD-8954 (pEC50 = 8.6) > tegaserod (pEC50 = 7.9) > prucalopride (pEC50 = 7.7) > cisapride (pEC50 = 7.0) > mosapride (pEC50 = 5.4). TD-8954 had a mean IA (55% of the 5-HT maximum) lower than that of cisapride and prucalopride (75 and 81%, respectively), but higher than that of tegaserod (45%) and mosapride (37%; Table 1). Incubation of tissues with the selective 5-HT4 receptor antagonist, piboserod (0.3 μM), resulted in a 614-fold shift (apparent pKa value = 9.3) of the TD-8954 concentration–response curve (data not shown).

Table 1 | Binding affinity (pKi) of TD-8954 at 5-HT receptor subtypes.

| Receptor Radioligand | [Radioligand] (nM) | pKi |
|-----------------------|-------------------|-----|
| Human 5-HT1A          | [3H]-8-OH-DPAT    | 0.6 | <6  |
| Rat 5-HT1B            | [3H]-CYP          | 0.1 | <6  |
| Bovine 5-HT1D         | [3H]-serotonin    | 2   | <6  |
| Human 5-HT2A          | [3H]-ketanserin   | 0.5 | <6  |
| Human 5-HT2B          | [3H]-LSD         | 1.2 | <6  |
| Human 5-HT2C          | [3H]-mesulergine  | 1   | <6  |
| Human 5-HT3A          | [3H]-GR6630       | 0.4 | <6  |
| Human 5-HT3C          | [3H]-GR113808     | 0.15| 9.4 |
| Human 5-HT5a          | [3H]-LSD         | 1   | <6  |
| Human 5-HT5g          | [3H]-LSD         | 2   | <6  |
| Human 5-HT7           | [3H]-LSD         | 4   | <6  |

Inhibition of radioligand binding to non-5-HT4 receptor subtypes was determined in duplicate at a single test concentration (1 μM, with the exception of the 5-HT2a receptor subtype, at which concentrations up to 100μM were evaluated).

Table 2 | Binding affinity (pKi) of TD-8954 at 5-HT receptor subtypes.

| Receptor Radioligand | [Radioligand] (nM) | pKi |
|-----------------------|-------------------|-----|
| Human 5-HT1A          | [3H]-8-OH-DPAT    | 0.6 | <6  |
| Rat 5-HT1B            | [3H]-CYP          | 0.1 | <6  |
| Bovine 5-HT1D         | [3H]-serotonin    | 2   | <6  |
| Human 5-HT2A          | [3H]-ketanserin   | 0.5 | <6  |
| Human 5-HT2B          | [3H]-LSD         | 1.2 | <6  |
| Human 5-HT2C          | [3H]-mesulergine  | 1   | <6  |
| Human 5-HT3A          | [3H]-GR6630       | 0.4 | <6  |
| Human 5-HT3C          | [3H]-GR113808     | 0.15| 9.4 |
| Human 5-HT5a          | [3H]-LSD         | 1   | <6  |
| Human 5-HT5g          | [3H]-LSD         | 2   | <6  |
| Human 5-HT7           | [3H]-LSD         | 4   | <6  |

Inhibition of radioligand binding to non-5-HT4 receptor subtypes was determined in duplicate at a single test concentration (1 μM, with the exception of the 5-HT2a receptor subtype, at which concentrations up to 100μM were evaluated).

Table 1 | Human 5-HT4(c) binding affinity (HEK293-h5-HT4(c); pKi), and human (HEK293-h5-HT4(c)) and guinea pig colonic longitudinal muscle/myenteric plexus (LMMP) agonist potency (pEC50) and intrinsic activity (IA; % 5-HT maximum) values for TD-8954, cisapride, mosapride, prucalopride, and tegaserod.

| Human 5-HT4(c) receptor affinity | Human 5-HT4(c) agonist activity | Guinea pig colonic LMMP contractile activity |
|----------------------------------|---------------------------------|-----------------------------------------------|
| pKi (mean ± SEM) | n | pEC50 (mean ± SEM) | IA (mean % 5-HT max ± SEM) | n | pEC50 (mean ± SEM) | IA (mean % 5-HT max ± SEM) | n |
| TD-8954 | 9.4±0.04 | 6 | 9.3±0.11 | 83±6 | 6 | 8.6±0.1 | 55±2 | 24 |
| Cisapride | 7.1±0.05 | 11 | 7.4±0.11 | 101±4 | 11 | 7.0±0.1 | 75±3 | 10 |
| Mosapride | 6.8±0.09 | 6 | 6.3±0.11 | 22±3 | 6 | 5.4±0.1 | 37±2 | 3  |
| Prucalopride | 7.6±0.03 | 11 | 7.9±0.11 | 109±5 | 11 | 7.7±0.1 | 81±2 | 24 |
| Tegaserod | 8.6±0.03 | 11 | 8.7±0.07 | 120±5 | 11 | 7.9±0.3 | 45±3 | 13 |
Table 3 | Binding data (% inhibition of specific binding and pKi values) of TD-8954 at non-5-HT receptors, transporters, ion channels, and enzymes.

| Receptor | Radioligand | [Radioligand] (nM) | % Inhibition of specific binding (1 μM) | pKi |
|----------|-------------|--------------------|----------------------------------------|-----|
| **BIOGENIC AMINE RECEPTORS** | | | | |
| Human A₁ | [³H]-DPCPX | 1 | −4 | <6 |
| Human A₂A | [³H]-CGS 21680 | 6 | −16 | <6 |
| Rat α₁ (non-selective) | [³H]-prazosin | 0.25 | −1 | <6 |
| Rat α₂ (non-selective) | [³H]-RX 821002 | 0.5 | 7 | <6 |
| Human D₁ | [³H]-SCH 23390 | 0.3 | −2 | <6 |
| Human D₂S | [³H]-spiperone | 0.3 | 6 | <6 |
| Human D₄₄ | [³H]-spiperone | 0.3 | 6 | <6 |
| Human D₅ | [³H]-SCH 23390 | 0.3 | −12 | <6 |
| Guinea pig H₁ | [³H]-pyrilamine | 1 | −7 | <6 |
| Guinea pig H₂ | [¹²⁵I]-APT | 0.1 | 4 | <6 |
| Human M₁ | [³H]-NMS | 1 | − | <6 |
| Human M₂ | [³H]-NMS | 1 | − | 6.1 |
| Human M₃ | [³H]-NMS | 1 | − | <5 |
| Human M₄ | [³H]-NMS | 1 | − | 5.5 |
| Human M₅ | [³H]-NMS | 1 | − | <5 |
| Human β₁ | [³H]-DHA | 0.8 | −8 | <6 |
| Human β₂ | [³H]-DHA | 0.8 | −17 | <6 |
| **PEPTIDE RECEPTORS** | | | | |
| Human AT₁ | [¹²⁵I]-[Sar¹, Ile⁸]-ATII | 0.05 | 2 | <6 |
| Rat BB (non-selective) | [¹²⁵I]-[Tyr⁴]bombesin | 0.01 | 4 | <6 |
| Human B₂ | [³H]-bradykinin | 0.2 | 3 | <6 |
| Human CGRP | [¹²⁵I]-CGRPRα | 0.03 | −18 | <6 |
| Human CCK₁ (CCK₆) | [¹²⁵I]-CCK-8 | 0.08 | −8 | <6 |
| Human CCK₂ (CCK₉) | [¹²⁵I]-CCK-8 | 0.06 | −1 | <6 |
| Rat CRF₁ | [¹²⁵I]-Tyr⁰-CRF | 0.1 | −6 | <6 |
| Human ET₁ | [¹²⁵I]-endothelin-1 | 0.03 | 0 | <6 |
| Human ET₂ | [¹²⁵I]-endothelin-1 | 0.03 | 5 | <6 |
| Rat galanin (non-selective) | [¹²⁵I]-galanin | 0.05 | 1 | <6 |
| Human motilin | [¹²⁵I]-motilin | 0.05 | 14 | <6 |
| Human NK₁ | [¹²⁵I]-[Sar², Met(O₂)ⁱ⁷]-SP | 0.15 | −2 | <6 |
| Human NK₂ | [¹²⁵I]-NKA | 0.1 | −8 | <6 |
| Human NK₃ | [³H]-SR 142801 | 0.4 | −3 | <6 |
| Human Y₁ | [¹²⁵I]-peptide YY | 0.025 | −11 | <6 |
| Human Y₂ | [¹²⁵I]-peptide YY | 0.015 | −5 | <6 |
| Rat NT (non-selective) | [¹²⁵I]-Tyr²-neurotensin | 0.05 | 4 | <6 |
| Rat PACAP (PAC₁) | [¹²⁵I]-PACAP₁₋₂⁷ | 0.02 | −3 | <6 |
| Mouse sst (non-selective) | [¹²⁵I]-Tyr¹⁷-somatostatin | 0.05 | −6 | <6 |
| Human VPAC₁ (VIP₁) | [¹²⁵I]-VIP | 0.04 | 2 | <6 |
| Human VPAC₂ (VIP₂) | [¹²⁵I]-VIP | 0.05 | −19 | <6 |
| Human V₁₃ | [³H]-AVP | 0.3 | 1 | <6 |
| Human V₂ | [³H]-AVP | 0.3 | −11 | <6 |
| **OPIATE RECEPTORS** | | | | |
| Human κ₂ | [³H]-DADLE | 0.5 | 0 | <6 |
| Guinea pig κ kappa | [³H]-U69593 | 0.7 | 22 | <6 |
| Human μ | [³H]-DAMGO | 0.5 | −30 | <6 |
| **TRANSPORTERS** | | | | |
| Human norepinephrine | [³H]-nisoxetine | 1 | 6 | <6 |
| Rat dopamine | [³H]-GBR12935 | 0.8 | 3 | <6 |
| Human 5-HT | [³H]-imipramine | 2 | 0 | <6 |

(Continued)
Table 3 | Continued

| Receptor                              | Radioligand               | [Radioligand] (nM) | % Inhibition of specific binding (1 μM) | pKi  |
|---------------------------------------|---------------------------|-------------------|----------------------------------------|------|
| **ION CHANNELS**                      |                           |                   |                                        |      |
| Rat AMPA                              | [3H]-AMPA                 | 8                 | −4                                     | <6   |
| Rat kainate                           | [3H]-kainic acid          | 5                 | −6                                     | <6   |
| Rat NMDA                              | [3H]-CGP 39653            | 5                 | −6                                     | <6   |
| Rat αβ2 nAChR (α-BGTX-insensitive)    | [3H]-cytisine             | 1.5               | −2                                     | <6   |
| Rat α7 nAChR (α-BGTX-sensitive)       | [125I]-α-bungarotoxin     | 1                 | 3                                      | <6   |
| Rat Ca2+ channel (L, DHP site)        | [3H]-(+)-IPN 200-110      | 0.04              | 7                                      | <6   |
| Rat Ca2+ channel (L, diltiazem site)  | [3H]-diltiazem            | 5                 | 13                                     | <6   |
| Rat Ca2+ channel (L, verapamil site)  | [3H]-(−)-D 888            | 0.5               | 21                                     | <6   |
| Rat Ca2+ channel (N)                  | [125I]-ω-conotoxin        | 0.001             | −11                                    | <6   |
| K+ATP channel                         | [3H]-glibenclamide        | 0.1               | 5                                      | <6   |
| K+V channel                           | [125I]-α-dendrotoxin      | 0.01              | −5                                     | <6   |
| SK+Ca channel                         | [125I]-apamin             | 0.004             | −4                                     | <6   |
| **OTHER**                             |                           |                   |                                        |      |
| Human CB1                              | [3H]-WIN 55212-2          | 2                 | 8                                      | <6   |
| Rat GABA (non-selective)              | [3H]-GABA                 | 10                | −6                                     | <6   |
| Rat P2Y                               | [35S]-dATP μS             | 10                | 8                                      | <6   |
| Rat α (non-selective)                 | [3H]-DTG                  | 8                 | 30                                     | <6   |
| **Enzyme**                            | Substrate/stimulus/tracer | [Substrate/stimulus/tracer] (μM) | % Inhibition of control (1 μM) | pIC50 |
| Human COX1                             | Arachidonic acid          | 0.3               | 2                                      | <6   |
| Human COX2                             | Arachidonic acid          | 50                | −36                                    | <6   |
| Human PDE4                             | [3H]-cAMP + cAMP          | 1                 | −19                                    | <6   |
| Rat adenylyl cyclase                   | ATP                       | 500               | 5                                      | <6   |
| Human acetylcholinesterase            | AMTCh                     | 50                | 2                                      | <6   |

**GUINEA PIG COLONIC TRANSIT**

In vehicle (2 mL/kg s.c.)-treated guinea pigs, the mean time taken for excretion of the first fecal pellet containing red dye was typically between 220 and 310 min. Following s.c. dosing, TD-8954, tegaserod, cisapride, mosapride (each at 0.03–3 mg/kg) and prucalopride (0.03–10 mg/kg) increased colonic transit, reducing the time taken for excretion of the dye, compared to vehicle-treated animals (Figure 3), although statistical significance (p < 0.05, one-way ANOVA with a Dunnett’s post hoc test) was achieved only for all of the TD-8954 doses and for the 0.3 and 3 mg/kg prucalopride.
doses. TD-8954 was more potent than tegaserod, prucalopride, cisapride, and mosapride, being significantly active at the lowest dose tested (0.03 mg/kg). At 0.03 mg/kg, TD-8954 had already achieved its maximum effect.

**RAT ESOPHAGEAL RELAXATION**

Following crystal placement on the rat esophagus, 30 min proved sufficient to establish a stable sonomicrometry recording. No spontaneous changes in esophageal muscle length were observed after this stabilization period. Following cumulative i.d. dosing, TD-8954, prucalopride, tegaserod (each 0.03–10 mg/kg), cisapride (0.3–10 mg/kg), and mosapride (0.3–10 mg/kg), but not their vehicles (1–10 mL/kg) evoked a dose-dependent increase in inter-crystal distance, consistent with esophageal relaxation (Figure 4). The ED50 values (with 95% confidence limits) for TD-8954 and prucalopride were 0.15 (0.08–0.26) and 0.18 (0.13–0.25) mg/kg, respectively. Accurate ED50 values could not be calculated for tegaserod, cisapride, and mosapride as solubility limitations precluded verification that their maximum relaxations had been achieved. To compare the potencies of each compound, the doses of TD-8954, prucalopride, tegaserod, cisapride, and mosapride associated with a relaxation response of 0.1 mm were calculated (i.e., 0.23, 0.30, 2.43, 2.66, and 4.37 mg/kg, respectively; Figure 4). TD-8954 was therefore equieffective, on a dose basis, with prucalopride following i.d. dosing, and 11-, 12-, and 19-fold more potent than tegaserod, cisapride, and mosapride, respectively.

**DOG GASTROINTESTINAL CONTRACTILITY**

The quiescent phase of the antrum, duodenum, and jejunum motility cycle generally lasted for 50–60 min before transitioning into the pre-burst period (muscle contractions of gradually increasing magnitude occurring at random, with a duration of 30–60 min), followed by the burst period (vigor and frequent contractions, with a duration of 5–15 min). Following oral administration of vehicle (1 mL/kg), there was little or no change in the activity of the antrum, duodenum, or jejunum; the expected motility patterns characteristic of fasted beagles were maintained throughout the observation period (Figures 5 and 6). TD-8954 (0.01 and 0.03 mg/kg) and tegaserod (0.1 and 0.3 mg/kg) produced increases in contractility in the antrum, duodenum, and jejunum (Figure 5). The onset of contractile activity with TD-8954 occurred typically within 10 min of dosing (Figure 6). Comparison of the activities of TD-8954 and tegaserod indicated that TD-8954 was statistically significantly more potent than tegaserod in the antrum, duodenum, and jejunum following oral administration (p < 0.05, ANOVA, followed by Dunnett’s post hoc test).
FIGURE 5 | Contractile activity following oral dosing of TD-8954 (0.01 and 0.03 mg/kg; \( n = 5 \); left-hand columns), tegaserod (0.1 and 0.3 mg/kg; \( n = 6 \); right-hand columns), and vehicles (\( n = 5 \) or 6) in the canine antrum, duodenum, and jejunum. Data are expressed as the mean (±SEM) cumulative contractile AUC in 10-min periods for 3 h post-dosing (at 0 min). Data are analyzed using a two-way analysis of variance with a Bonferroni post hoc test (*, # \( p < 0.05 \) for the 0.01, 0.03, and 0.3 mg/kg treatment groups, respectively, vs. vehicle).

HUMAN SINGLE ASCENDING DOSE STUDY

In healthy human subjects, GI prokinetic effects of TD-8954 (0.1–20 mg) were observed (Figure 7). The number of bowel movements from 0 to 24 h after each TD-8954 dose was increased significantly relative to placebo (\( p < 0.03 \) upon comparison of each TD-8954 treated group and placebo, based on Wilcoxon rank sum test). Compared to placebo, each TD-8954 dose was associated with a statistically significant reduction in the time to first bowel movement (\( p < 0.05 \) for all treatment groups comparing difference in survival function between each TD-8954 treated group and placebo obtained by log-rank test).
DISCUSSION

Dyspepsia have a significant impact on the quality of life of affected individuals. Prior to their removal from the market, cisapride and tegaserod provided some relief to patients afflicted with these disorders (Prather et al., 2000; Evans et al., 2004; Ford et al., 2009). Limitations in their efficacy have been attributed to a lack of selectivity for the 5-HT4 receptor subtype (Beattie and Smith, 2008; De Maeyer et al., 2008). Cisapride is a potent 5-HT2A and 5-HT2B receptor antagonist, while tegaserod has affinity for, and/or antagonist potency at, 5-HT1B, 5-HT2A, and 5-HT3A receptors (Buchheit et al., 1995; Beattie et al., 2004; De Maeyer et al., 2008). Interactions of cisapride or tegaserod with non-5-HT receptors have also been proposed to underlie cardiac arrhythmic or ischemic adverse events. It is now well established that cisapride can induce ventricular tachycardia, ventricular fibrillation, and torsades de pointes as a result of potent cardiac hERG potassium channel inhibitory activity, particularly when cytochrome P450 3A4 substrates are co-administered (Mohammad et al., 1997). The perceived risk of cardiovascular ischemic events with tegaserod, initially identified upon reviewing clinical trial data, has been questioned recently (Anderson et al., 2009; Loughlin et al., 2010). It is clear, however, that a significant unmet medical need remains for new therapeutic agents that will be efficacious and well tolerated in patients with functional GI disorders. One approach has been the development of selective 5-HT4 receptor agonists, such as velusetrag (Beattie et al., 2008a; Smith et al., 2008; Goldberg et al., 2010), prucalopride (Briejer et al., 2001a; Camilleri et al., 2008), and TD-8954 (Beattie et al., 2008b), which, it is believed, will provide robust efficacy with acceptable tolerability and safety for patients. TD-8954, the subject of this study, is one of the most potent and selective 5-HT4 receptor agonists described to date.

The in vitro data demonstrated that TD-8954 had high affinity and potency at the human 5-HT4 receptor (pKi and pEC50 values of 9.4 and 9.3, respectively). In each assay, TD-8954 was significantly more potent than each of the comparator 5-HT4 agonists tested in parallel, an observation consistent with that made previously in experiments with human isolated colonic circular muscle preparations (Beattie et al., 2008b). Activation of the 5-HT4 receptor by TD-8954 was confirmed in vitro by antagonist inhibition, where the GR113808 pKb value was consistent with the [3H]-GR113808 binding pKd and antagonist pKb values reported previously against 5-HT and tegaserod (Smith et al., 2008), providing further evidence of a 5-HT4 receptor-mediated elevation of cAMP. TD-8954 had moderate IA at human recombinant 5-HT4 receptors and endogenous 5-HT4 receptors in the guinea pig colonic LMMP. Optimal target activation to induce a physiological response is dependent upon, amongst other things, the IA of an agonist and the receptor reserve in the target tissue (Grimwood and Hartig, 2009). While TD-8954 had moderate IA at human recombinant 5-HT4 receptors and endogenous 5-HT4 receptors in the guinea pig colonic LMMP. Optimal target activation to induce a physiological response is dependent upon, amongst other things, the IA of an agonist and the receptor reserve in the target tissue (Grimwood and Hartig, 2009).
affinity for 5-HT\textsubscript{1B}, 5-HT\textsubscript{2A}, 5-HT\textsubscript{2B}, or 5-HT\textsubscript{3} receptors. Also, in contrast to cisapride, TD-8954 had no inhibitory effect at the hERG potassium channel.

The high 5-HT\textsubscript{4} receptor agonist potency of TD-8954 was also evident in vivo. TD-8954 (0.03–3 mg/kg s.c.) produced a statistically significant increase in colonic transit in conscious guinea pigs. Following TD-8954 administration and injection of carmine red dye into the proximal colon, the time for excretion of the first fecal pellet containing the marker was markedly reduced. The potent prokinetic activity of TD-8954 in this guinea pig model is in keeping with the proposed role of 5-HT and 5-HT\textsubscript{4} receptor activation in promoting GI motility (Muller-Lissner, 1987; Jia et al., 2003). The TD-8954-induced relaxation of the rat esophagus in this study is also consistent with agonist activity at the 5-HT\textsubscript{4} receptor (Triggie et al., 1988; Reeves et al., 1991). The technique of digital sonomicrometry provides a sensitive method to demonstrate the 5-HT\textsubscript{4} receptor agonist-mediated changes in rat esophageal tone (Armstrong et al., 2006).

In conscious, fasted dogs, TD-8954 (10 and 30 μg/kg) produced a dose-dependent increase in contractility of the antrum, duodenum, and jejunum following oral administration. TD-8954 was clearly more potent than tegaserod throughout the canine GI tract, consistent with its superior 5-HT\textsubscript{4} agonist potency in vitro and oral pharmacokinetic properties (Theravance, Inc., data on file) in this species. Considering the published data from similar models (Gullikson et al., 1993; Briejer et al., 2001b; Tazawa et al., 2002), the findings of this study are entirely consistent with activation of 5-HT\textsubscript{4} receptors by TD-8954 in the canine GI tract.

Based on the positive preclinical pharmacodynamic effects of TD-8954, a single ascending dose study was performed in healthy human subjects. The data demonstrated that TD-8954 was associated with an increase in bowel movement frequency and a reduction in the time to first stool compared to placebo. The high potency noted in the preclinical assays was also noted clinically; a dose as low as 0.1 mg was associated with a prokinetic effect, and 0.5 mg produced a maximal response. The free plasma C\textsubscript{max} and AUC\textsubscript{0–24} values for TD-8954 following a single dose of 0.5 mg to humans are 3.4 and 36.2 nM/h, respectively. Assuming that the free concentration of TD-8954 in plasma is equivalent to that at its site of action in the GI tract, mean and maximal 5-HT\textsubscript{4} receptor occupancies in the 24-h period following a 0.5 mg dose should be approximately 80 and 90%, respectively. This apparent requirement for a high level of receptor occupancy to achieve a maximal agonist response (Grimwood and Hartig, 2009) is consistent with the moderate IA of TD-8954 demonstrated preclinically in the in vitro assays.

**CONCLUSION**

TD-8954 is a potent and selective 5-HT\textsubscript{4} receptor agonist in vitro with robust in vivo GI activity in guinea pigs, rats, dogs, and notably humans. As a result of its demonstrated prokinetic activity in healthy human subjects, TD-8954 may have value in the treatment of patients with disorders of reduced GI motility.

**ACKNOWLEDGMENTS**

The authors would like to thank Shanti Amagasu, Courtney Gee, Ngoc Mai, Tina Pham, John Taylor, and Shana Johnson Rabidoux for their assistance with the experiments, and Fei Shen, Uwe Klein, and Ed Moran for their critique of the manuscript.
Camilleri, M., Kerstens, R., Rykk, A., and Vandeloo, L. (2008). A placebo-controlled trial of prucalor- pride for severe chronic constipation. Neurourol. Urodyn. 27(4), 455–463.

Cheng, Y. and Prussow, W. H. (1973). Relationship between the inhibition constant (K1) and the concentra- tion of inhibitor which causes 50 per cent inhibition (IS0) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108.

De Maeyer, J. H., Leemans, R., and Vandecappelle, L. (2008). 5-HT4 receptor agonists: similar but not the same. Neuropeptides 42, 216–226.

Dertinger, M., Lepore, L., Heylen, H., Samin, H., and Pennout, H. (1976). 5-HT3 receptor in the manage- ment of chronic functional dyspepsia: a multicenter, double-blind, placebo-controlled study. Clin. Ther. 10, 44–51.

Evans, B. W., Clark, W. K., Moore, D. J., and Whorrell, P. J. (2004). Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 14, 44.

Ford, A. C., Brandt, L. J., and Young, C. (2003). Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea-pig intestine. Gastroenterology 115, 370–380.

Grimm, S., and Hartig, P. R. (2009). Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol. Ther. 122, 281–301.

Guilkison, G. W., Virina, M. A., Loeffler, R. F., Yang, D. C., Goldbstein, B., Wang, S. X., Moumeni, C., Flynn, D., and Bazarov, D. L. (1993). SCG-95158 enhances gastric emptying of solid and liquid meals and stimulates gas- trointestinal motility in dogs by a 5-hydroxytryptamine4 receptor mechanism. J. Pharmacol. Exp. Ther. 264, 240–248.

Hansen, M. B., and Skadhauge, E. (1997). Signal transduction path- ways for serotonin as an intesti- nal secretagogue. Comp. Biochem. Physiol. 118, 283–290.

Hillier, K., Tam, F. S. F., Bunce, K. T., and Grossman, C. (1994). Inhibition of motility induced by the activa- tion of 5-HT1 and 5-HT4 recep- tor types in isolated human colon smooth muscle. Br. J. Pharmacol. 112, 102P.

Inui, A., Yoshikawa, T., Nagai, R., Yoshida, N., and Ito, T. (2002). Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonic motility in conscious guinea pigs. Ipn. J. Pharmacol. 90, 313–320.

Ito, M., Mueller, U., Kocher, T., Haier, J., Wieczorek, G., and Pfannkuche, H.-J. (2003). Distribution of 5-HT4 receptor splice variants in the human and non-human primate gastro- intestinal tract. Neurogastroenterol. Motil. 15, 498.

Ji, S. W., Park, H., Cho, J. S., and Lee, S. I. (2003). Investigation into the effects of mosapride on motility of guinea pig ileum, ileum, and colon. Yonsei Med. J. 44, 653–664.

Jin, J. G., Foxx-Orenstein, A. E., and Green, J. R. (1999). Propulsion in guinea pig ileum induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J. Pharmacol. Exp. Ther. 288, 93–97.

Johanson, J. F. (2004). Review article: tegaserod for chronic constipation. Aliment. Pharmacol. Ther. 20(Suppl. 7), 20–24.

Kadowaki, M., Wade, P. R., and Ger- shon, M. D. (1996). Participation of 5-HT3, 5-HT4, and nicotinic recep- tors in the peristaltic reflex of guinea pig distal colon. Am. J. Physiol. 271, G469–G467.

Kaumann, A. J., and Levy, F. O. (2006). 5-hydroxytryptamine recep- tors in the human cardiovascular system. Pharmacol. Ther. 111, 674–706.

Kellow, J. E., Cowan, H., Shuter, B., Riley, J. W., Ljunger, M. R., Eckstein, R. P., Höschl, R., and Lam, S.-K. (1995). Efficacy of cis- apride therapy in functional dys- phagia. Aliment. Pharmacol. Ther. 9, 153–160.

Kenakin, T. (1997). Pharmacologic Analysis of Drug-Receptor Interac- tion. Philadelphia: Lippincott- Raven, 331–373.

Kim, D.-Y., and Camilleri, M. (2000). Serotonin: a mediator of the brain-gut connection. Am. J. Gastroenterol. 95, 2799–2799.

Kirchgesner, A. L., Tamir, H., and Gershon, M. D. (1992). Identification and stimulation by serotonin of intrinsic sensory neurons of the submucosal plexus of the guinea pig gut: activity-induced expression of Fos immunoreactivity. J. Neurosci. 12, 235–248.

Loughlin, J., Quinn, S., Rivero, E., Wong, J., Huang, J., Kralstein, J., Earnest, D. L., and Seeger, J. D. (2010). Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J. Cardiovasc. Pharmacol. Ther. 15, 151–157.

Manabe, N., Wong, B. S., and Camilleri, M. (2010). New-generation 5-HT4 receptor agonists: potential for treat- ment of gastrointestinal motility disor- ders. Exp. Opin. Investig. Drugs 19, 765–775.

Manini, M. L., Camilleri, M., Gold- berg, M., Sweetser, S., Mckinzie, S., Burton, D., Wong, S., Kitt, M. M., Li, Y.-P., and Zinsmeister, A. R. (2009). Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and phar- macokinetics in health and constipa- tion. Neurogastroenterol. Motil. 22, 42–48.

Medhurst, A. D., Lezoualch, F., Fischmeister, R., Middendorf, D. N., and Sanger, G. J. (2001). Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous sys- tem by TaqMan real time RT-PCR. Brain Res. Mol. Brain Res. 90, 125–134.

Mohammad, S., Zhou, Z., Gong, Q., and January, C. T. (1997). Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol. 273, H2534–H2538.

Müller-Lissner, S. A. (1987). Treat- ment of chronic constipation with cisapride and placebo. Gut 28, 1033–1038.

Pasricha, P. J. (2007). Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug develop- ment for functional and motil- ity disorders. Gastroenterology 132, 2387–2390.

Pitel, S., Berra, D., and Lembo, A. (2004). Review of tegaserod in the treatment of irritable bowel syn- drome. Exp. Opin. Pharmacother. 5, 2369–2379.

Prather, C. M., Camilleri, M., Zinsmeister, A. R., Mckinzie, S., and Thom- forde, G. (2000). Tegaserod acceler- ates oroecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 118, 463–468.

Reeves, J. J., Bunce, K. T., and Humphrey, P. P. A. (1991). Investiga- tion into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat esoph- agus. Br. J. Pharmacol. 102, 1067–1072.

Sanger, G. J. (2008). 5-Hydroxytrypt- amine and the gastrointestinal tract: where next? Trends Pharmacol. Sci. 29, 465–471.

Sanger, G. J. (2009). Translating 5-HT4 receptor pharmacology. Neurogastroenterol. Motil. 21, 1235–1238.

Smith, J. A., Amagasa, S. M., Hern- brador, J., Axt, S., Chang, R., Church, T., Gee, C., Jacobsen, J. R., Jenk- ins, T., Kaufman, E., Mai, N., and Vickery, R. G. (2006). Evi- dence for a multivariant interac- tion of symmetrical, N-linked, litho- caine dimers with voltage-gated Na+ channels. Mol. Pharmacol. 69, 921–931.

Smith, J. A. M., Beattie, D. T., Marquess, D., Shaw, I.-P., Vick- ery, R. G., and Humphrey, P. P. A. (2008). The in vitro pharma- cological profile of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch. Pharmacol. 378, 125–137.
Tazawa, S., Masuda, N., Koizumi, T., Kitazawa, M., Nakane, T., and Miyata, H. (2002). KDR-5169, a new gastrointestinal prokinetic agent, enhances gastric contractile and emptying activities in dogs and rats. Eur. J. Pharmacol. 434, 169–176.

Triggle, C. R., Ohia, S. E., and Bieger, D. (1988). 5-Hydroxytryptamine-induced relaxation of rat and mouse oesophageal smooth muscle. Pharmacologist 30, A126.

Vickery, R. G., Mai, N., Kaufmann, E., Beattie, D. T., Pulido-Rios, T., O’Keeffe, M., Humphrey, P. P., and Smith, J. A. (2007). A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptors. Br. J. Pharmacol. 150, 782–791.

Conflict of Interest Statement: The authors are current or former employees of Theravance, Inc., and may own stock of Theravance, Inc.

Received: 13 April 2011; paper pending published: 30 April 2011; accepted: 16 May 2011; published online: 30 May 2011.

Citation: Beattie DT, Armstrong SR, Vickery RG, Tsuruda PR, Campbell CB, Richardson C, McCullough JL, Daniels O, Kersey K, Li Y-P and Kim KHS (2011) The pharmacology of TD-8954, a potent and selective 5-HT4 receptor agonist with gastrointestinal prokinetic properties. Front. Pharmacol. 2:25. doi: 10.3389/fphar.2011.00025

This article was submitted to Frontiers in Gastrointestinal Pharmacology, a specialty of Frontiers in Pharmacology. Copyright © 2011 Beattie, Armstrong, Vickery, Tsuruda, Campbell, Richardson, McCullough, Daniels, Kersey, Li and Kim. This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.